They show stand up to cancer on Slide 12. I like their game plan on solid tumors/sgi-110 and what they needed to find in hypomethylation in the tumor. They have a game plan to move it further along as long as they see something materially in the tumor response.
There was some key points on the sgi-110 or AT3387 that a key biomarker was found that maybe useful on identifying who will benefit the most. I wrote the point down, but forgot which drug it was.
The third compound to have an update in Dec was suppose to be AT7519. With our luck they have a snag and the street will spank us 10%.
AT 7519 has vanished not on website not on slides. Hopefully they will mention they dropped it after announcing positive S110 results at ASH Dont you agree this leads to a lack of credbility by analysts Im all for not wasting time and money on compounds that dont perform in the clinic but there is a better way to do it.